UNSPSC 51381504: Mefenamic acid

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 367589PJ2C, chemically known as 2-diphenylaminecarboxylic acid, 2,3-dimethyl- but generally known as mefenamic acid, which bears US NIH Compound Identifier 4044. European Medicines Agency schedules Mefenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08703MIG.

UNSPSC 51381504 Mefenamic acid is a Commodity code that in recent state and local procurement covers the sourcing and delivery of pharmaceutical products including naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products to support public health, community health, and pharmacy benefit programs. The issuing bodies soliciting under this code span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Work solicited includes the procurement of finished pharmaceutical inventory for community health initiatives, direct-to-manufacturer prescription programs, and generic pharmaceutical products distributed through authorized wholesalers to state and local government facilities. Vendors must comply with FDA requirements, current Good Manufacturing Practices, the Drug Supply Chain Security Act, and various federal environmental regulations when applicable; contracts typically require proof of legal authorization to work in the United States, drug-free workplace certification, E-Verify compliance, and specified insurance coverages including general liability and professional liability.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with response due April 3, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with proposals due March 26, 2026 and contract awards effective July 1, 2026; pricing evaluation weighted 75 percent of total score, with vendors required to maintain relationships with at least two of three authorized wholesalers and pay a 3 percent administrative fee on all contract purchases.